{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:32:18Z","timestamp":1760236338162,"version":"build-2065373602"},"reference-count":91,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST-110-2320-B-006-028"],"award-info":[{"award-number":["MOST-110-2320-B-006-028"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Solifenacin (Vesicare\u00ae, SOL), known to be a member of isoquinolines, is a muscarinic antagonist that has anticholinergic effect, and it has been beneficial in treating urinary incontinence and neurogenic detrusor overactivity. However, the information regarding the effects of SOL on membrane ionic currents is largely uncertain, despite its clinically wide use in patients with those disorders. In this study, the whole-cell current recordings revealed that upon membrane depolarization in pituitary GH3 cells, the exposure to SOL concentration-dependently increased the amplitude of M-type K+ current (IK(M)) with effective EC50 value of 0.34 \u03bcM. The activation time constant of IK(M) was concurrently shortened in the SOL presence, hence yielding the KD value of 0.55 \u03bcM based on minimal reaction scheme. As cells were exposed to SOL, the steady-state activation curve of IK(M) was shifted along the voltage axis to the left with no change in the gating charge of the current. Upon an isosceles-triangular ramp pulse, the hysteretic area of IK(M) was increased by adding SOL. As cells were continually exposed to SOL, further application of acetylcholine (1 \u03bcM) failed to modify SOL-stimulated IK(M); however, subsequent addition of thyrotropin releasing hormone (TRH, 1 \u03bcM) was able to counteract SOL-induced increase in IK(M) amplitude. In cell-attached single-channel current recordings, bath addition of SOL led to an increase in the activity of M-type K+ (KM) channels with no change in the single channel conductance; the mean open time of the channel became lengthened. In whole-cell current-clamp recordings, the SOL application reduced the firing of action potentials (APs) in GH3 cells; however, either subsequent addition of TRH or linopirdine was able to reverse SOL-mediated decrease in AP firing. In hippocampal mHippoE-14 neurons, the IK(M) was also stimulated by adding SOL. Altogether, findings from this study disclosed for the first time the effectiveness of SOL in interacting with KM channels and hence in stimulating IK(M) in electrically excitable cells, and this noticeable action appears to be independent of its antagonistic activity on the canonical binding to muscarinic receptors expressed in GH3 or mHippoE-14 cells.<\/jats:p>","DOI":"10.3390\/ijms222212399","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T09:16:11Z","timestamp":1637140571000},"page":"12399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Effectiveness in Activating M-Type K+ Current Produced by Solifenacin ([(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate): Independent of Its Antimuscarinic Action"],"prefix":"10.3390","volume":"22","author":[{"given":"Hsin-Yen","family":"Cho","sequence":"first","affiliation":[{"name":"Department of Physiology, National Cheng Kung University Medical College, Tainan City 70101, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hsien","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Physiology, National Cheng Kung University Medical College, Tainan City 70101, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-3253","authenticated-orcid":false,"given":"Sheng-Nan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Physiology, National Cheng Kung University Medical College, Tainan City 70101, Taiwan"},{"name":"Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan City 70101, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1358\/dot.2004.40.4.820080","article-title":"Solifenacin: Treatment of overactive bladder","volume":"40","author":"Bosch","year":"2004","journal-title":"Drugs Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00002512-200522120-00005","article-title":"Solifenacin in Overactive Bladder Syndrome","volume":"22","author":"Simpson","year":"2005","journal-title":"Drugs Aging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ucl.2006.06.008","article-title":"Solifenacin","volume":"33","author":"Kreder","year":"2006","journal-title":"Urol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003495-200666020-00004","article-title":"Solifenacin in Overactive Bladder Syndrome","volume":"66","author":"Payne","year":"2006","journal-title":"Drugs"},{"key":"ref_5","first-page":"182","article-title":"Overactive Bladder: Pharmacologic Treatments in the Neurogenic Population","volume":"10","author":"Kennelly","year":"2008","journal-title":"Rev. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3810\/pgm.2008.07.1795","article-title":"Solifenacin at 3 years: A review of efficacy and safety","volume":"120","author":"Pelman","year":"2008","journal-title":"Postgrad. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-200948050-00001","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin","volume":"48","author":"Doroshyenko","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_8","first-page":"43","article-title":"Solifenacin pharmacology","volume":"63","year":"2010","journal-title":"Arch. Esp. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00192-011-1641-7","article-title":"Solifenacin for overactive bladder: A systematic review and meta-analysis","volume":"23","author":"Luo","year":"2012","journal-title":"Int. Urogynecol. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/nau.23863","article-title":"Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder","volume":"38","author":"Wang","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"ref_17","first-page":"24","article-title":"New Indication for Solifenacin","volume":"120","author":"Aschenbrenner","year":"2020","journal-title":"AJN Am. J. Nurs."},{"key":"ref_18","unstructured":"Mirzaei, M., Daneshpajooh, A., Anvari, S.O., Dozchizadeh, S., and Teimorian, M. (2021). Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial. Urol. J., 6274."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, S., Zu, S., and Zhang, C. (2021). Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253040"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11934-011-0198-9","article-title":"Antimuscarinic Drugs: Review of the Cognitive Impact When Used to Treat Overactive Bladder in Elderly Patients","volume":"12","author":"Pagoria","year":"2011","journal-title":"Curr. Urol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000350029","article-title":"The Effect of Solifenacin on Cognitive Function following Stroke","volume":"3","author":"Park","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1331\/JAPhA.2015.14288","article-title":"Potentially inappropriate anticholinergic medication use in older adults with dementia","volume":"55","author":"Kachru","year":"2015","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11606-020-05634-3","article-title":"Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: A Retrospective Study","volume":"35","author":"Kachru","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/03007995.2021.1920899","article-title":"Antimuscarinic use among older adults with dementia and overactive bladder: A Medicare beneficiaries study","volume":"37","author":"Kachru","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/gps.5467","article-title":"Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder","volume":"36","author":"Kachru","year":"2021","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40266-015-0281-x","article-title":"Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations","volume":"32","author":"Orme","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yang, Y.-W., Liu, H.-H., Lin, T.-H., Chuang, H.-Y., and Hsieh, T. (2017). Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175335"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13685538.2017.1398723","article-title":"Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage","volume":"21","author":"Kosilov","year":"2017","journal-title":"Aging Male"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/pds.5098","article-title":"Alzheimer\u2019s disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs","volume":"29","author":"Barthold","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: A population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1038\/s41598-021-84229-2","article-title":"Use of bladder antimuscarinics is associated with an increased risk of dementia: A retrospective population-based case\u2013control study","volume":"11","author":"Harnod","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1159\/000515992","article-title":"Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial","volume":"105","author":"Soliman","year":"2021","journal-title":"Urol. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0006-8993(99)02094-6","article-title":"Muscarinic regulation of Ca2+ oscillation frequency in GH3 cells","volume":"851","author":"Kushmerick","year":"1999","journal-title":"Brain Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0167-4889(84)90032-6","article-title":"Muscarinic acetylcholine receptor activation causes inhibition of cyclic AMP accumulation, prolactin and growth hormone secretion in GH3 rat anterior pituitary tumour cells","volume":"805","author":"Wojcikiewicz","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/endo-117-3-976","article-title":"Lowering of Cytosolic Free Ca2+ by Carbachol, a Muscarinic Cholinergic Agonist, in Clonal Pituitary Cells (GH 3 Cells)","volume":"117","author":"Schlegel","year":"1985","journal-title":"Endocrinology"},{"key":"ref_36","first-page":"411","article-title":"Mechanisms of action of inhibitors of prolactin secretion in GH3 pituitary cells. I. Ca2+-dependent inhibition of amino acid incorporation","volume":"29","author":"Wolfe","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(87)90038-2","article-title":"Carbachol changes spike-generation properties of GH3 pituitary cells","volume":"402","author":"Hedlund","year":"1987","journal-title":"Brain Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/0006-2952(88)90262-6","article-title":"The muscarinic receptor of rat pituitary GH3 cells is coupled with adenylate cyclase inhibition, but not with phosphoinositide turnover","volume":"37","author":"Hitoshi","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bbagen.2004.12.007","article-title":"Pretreatment with muscarinic receptor agonist activates a calcium-inhibitable adenylate cyclase in GH3 pituitary cells","volume":"1722","author":"Chou","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbrc.2008.08.110","article-title":"The Cu\u2013Zn superoxide dismutase (SOD1) inhibits ERK phosphorylation by muscarinic receptor modulation in rat pituitary GH3 cells","volume":"376","author":"Secondo","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"24983","DOI":"10.1016\/S0021-9258(19)73994-5","article-title":"The G alpha q and G alpha 11 proteins couple the thyrotropin-releasing hormone receptor to phospholipase C in GH3 rat pituitary cells","volume":"267","author":"Aragay","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/mend-1-4-283","article-title":"Reconstitution of somatostatin and muscarinic receptor mediated stimulation of K+ channels by isolated GK protein in clonal rat anterior pituitary cell membranes","volume":"1","author":"Yatani","year":"1987","journal-title":"Mol. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0026-0495(90)90220-7","article-title":"Direct coupling of the somatostatin receptor to potassium channels by a G protein","volume":"39","author":"Yatani","year":"1990","journal-title":"Metabolism"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1210\/mend-5-7-995","article-title":"Inhibition of Voltage-Dependent Ca2+Currents and Activation of Pertussis Toxin-Sensitive G-Proteins via Muscarinic Receptors in GH3Cells","volume":"5","author":"Offermanns","year":"1991","journal-title":"Mol. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1126\/science.282.5395.1890","article-title":"KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1476-5381.1992.tb14254.x","article-title":"M-currents in frog sympathetic ganglion cells: Manipulation of membrane phosphorylation","volume":"105","author":"Chen","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1139\/y92-238","article-title":"Regulation of the M current: Transduction mechanism and role in ganglionic transmission","volume":"70","author":"Smith","year":"1992","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1523\/JNEUROSCI.16-05-01668.1996","article-title":"Characterization of an M-like current modulated by thyrotropin- releasing hormone in normal rat lactotrophs","volume":"16","author":"Sankaranarayanan","year":"1996","journal-title":"J. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1523\/JNEUROSCI.19-18-07742.1999","article-title":"Two Types of K+ Channel Subunit, Erg1 and KCNQ2\/3, Contribute to the M-Like Current in a Mammalian Neuronal Cell","volume":"19","author":"Selyanko","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lo, Y.-C., Lin, C.-L., Fang, W.-Y., L\u0151rinczi, B., Szatm\u00e1ri, I., Chang, W.-H., F\u00fcl\u00f6p, F., and Wu, S.-N. (2021). Effective Activation by Kynurenic Acid and Its Aminoalkylated Derivatives on M-Type K+ Current. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031300"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Afeli, S.A.Y., Malysz, J., and Petkov, G.V. (2013). Molecular Expression and Pharmacological Evidence for a Functional Role of Kv7 Channel Subtypes in Guinea Pig Urinary Bladder Smooth Muscle. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075875"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/bph.12210","article-title":"Functional expression of KCNQ (Kv7) channels in guinea pig bladder smooth muscle and their contribution to spontaneous activity","volume":"169","author":"Anderson","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pharmthera.2016.05.002","article-title":"Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels","volume":"165","author":"Haick","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/epi.13978","article-title":"Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy","volume":"59","author":"Gautier","year":"2018","journal-title":"Epilepsia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"So, E.C., Foo, N.P., Ko, S.Y., and Wu, S.-H. (2019). Bisoprolol, Known to Be a Selective \u03b2\u2081-Receptor Antagonist, Differentially but Directly Suppresses I(K(M)) and I(K(erg)) in Pituitary Cells and Hippocampal Neurons. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030657"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1113\/jphysiol.1993.sp019967","article-title":"Potassium currents operated by thyrotrophin-releasing hormone in dissociated CA1 pyramidal neurones of rat hippocampus","volume":"472","author":"Ebihara","year":"1993","journal-title":"J. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/cn200065b","article-title":"Discovery, Synthesis, and Structure\u2013Activity Relationship of a Series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener","volume":"2","author":"Yu","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hsu, H.-T., Tseng, Y.-T., Lo, Y.-C., and Wu, S.-N. (2014). Ability of naringenin, a bioflavonoid, to activate M-type potassium current in motor neuron-like cells and to increase BKCa-channel activity in HEK293T cells transfected with \u03b1-hSlo subunit. BMC Neurosci., 15.","DOI":"10.1186\/s12868-014-0135-1"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/01.RES.69.5.1316","article-title":"Dynamics of the background outward current of single guinea pig ventricular myocytes. Ionic mechanisms of hysteresis in cardiac cells","volume":"69","author":"Delmar","year":"1991","journal-title":"Circ. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0306-3623(98)00056-1","article-title":"Effects of Quinidine, Verapamil, Nifedipine and Ouabain on Hysteresis in Atrial Refractoriness in the Conscious Dog: An Approach to Ionic Mechanisms","volume":"32","author":"Boucher","year":"1999","journal-title":"Gen. Pharmacol. Vasc. Syst."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bioelechem.2003.08.006","article-title":"Voltage activation and hysteresis of the non-selective voltage-dependent channel in the intact human red cell","volume":"62","author":"Bennekou","year":"2004","journal-title":"Bioelectrochemistry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00249-015-1049-2","article-title":"Conductance hysteresis in the voltage-dependent anion channel","volume":"44","author":"Rappaport","year":"2015","journal-title":"Eur. Biophys. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.1038\/ncomms10334","article-title":"Ionic polarization-induced current\u2013voltage hysteresis in CH3NH3PbX3 perovskite solar cells","volume":"7","author":"Meloni","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.bbamem.2016.02.026","article-title":"Current state of theoretical and experimental studies of the voltage-dependent anion channel (VDAC)","volume":"1858","author":"Noskov","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wu, S.-N., and Huang, C.-W. (2021). Editorial to the Special Issue \u201cElectrophysiology\u201d. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062956"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.108.136390","article-title":"In Vivo Quantitative Autoradiographic Analysis of Brain Muscarinic Receptor Occupancy by Antimuscarinic Agents for Overactive Bladder Treatment","volume":"325","author":"Maruyama","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/jpet.111.182857","article-title":"Influence of Tissue Integrity on Pharmacological Phenotypes of Muscarinic Acetylcholine Receptors in the Rat Cerebral Cortex","volume":"339","author":"Anisuzzaman","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuroscience.2010.06.076","article-title":"Estrogen receptor \u03b1 and G-protein coupled receptor 30 mediate the neuroprotective effects of 17\u03b2-estradiol in novel murine hippocampal cell models","volume":"170","author":"Gingerich","year":"2010","journal-title":"Neuroscience"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000489810","article-title":"Multiple Actions of Rotenone, an Inhibitor of Mitochondrial Respiratory Chain, on Ionic Currents and Miniature End-Plate Potential in Mouse Hippocampal (mHippoE-14) Neurons","volume":"47","author":"Huang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lai, M.-C., Wu, S.-N., and Huang, C.-W. (2020). The Specific Effects of OD-1, a Peptide Activator, on Voltage-Gated Sodium Current and Seizure Susceptibility. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218254"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1517\/13543776.2010.513384","article-title":"Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy","volume":"20","author":"Castle","year":"2010","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3389\/fphar.2020.01091","article-title":"Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I (K(M)) or I (K(DR)) and in the Stimulation of I (MEP)","volume":"11","author":"Chang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jchromb.2008.10.050","article-title":"Highly sensitive and rapid LC\u2013ESI-MS\/MS method for the simultaneous quantification of uroselective \u03b11-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma","volume":"876","author":"Mistri","year":"2008","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1016\/j.jchromb.2010.10.010","article-title":"Determination of solifenacin in human plasma by liquid chromatography-tandem mass spectrometry","volume":"878","author":"Macek","year":"2010","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e00684","DOI":"10.1002\/prp2.684","article-title":"Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity","volume":"8","author":"Tannenbaum","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1254\/jphs.FP0060754","article-title":"Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency","volume":"103","author":"Smulders","year":"2007","journal-title":"J. Pharmacol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14728222.8.5.437","article-title":"Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders","volume":"8","author":"Gopalakrishnan","year":"2004","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.juro.2009.02.108","article-title":"KCNQ Currents and Their Contribution to Resting Membrane Potential and the Excitability of Interstitial Cells of Cajal From the Guinea Pig Bladder","volume":"182","author":"Anderson","year":"2009","journal-title":"J. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2010.03.050","article-title":"Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder","volume":"638","author":"Rode","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"},{"key":"ref_82","first-page":"145","article-title":"Kv7 Positive Modulators Reduce Detrusor Overactivity and Increase Bladder Capacity in Rats","volume":"110","author":"Hansen","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejphar.2013.05.005","article-title":"Bladder contractility is modulated by Kv7 channels in pig detrusor","volume":"715","author":"Bille","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Sval\u00f8, J., Sheykhzade, M., Nordling, J., Matras, C., and Bouchelouche, P. (2015). Functional and Molecular Evidence for Kv7 Channel Subtypes in Human Detrusor from Patients with and without Bladder Outflow Obstruction. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117350"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2016.07.041","article-title":"Effects of K+ channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder","volume":"789","author":"Takagi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00210-016-1312-9","article-title":"K(V)7 channels in the human detrusor: Channel modulator effects and gene and protein expression","volume":"390","author":"Bientinesi","year":"2017","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/jpet.117.243162","article-title":"K(V)7 Channel Pharmacological Activation by the Novel Activator ML213: Role for Heteromeric K(V)7.4\/K(V)7.5 Channels in Guinea Pig Detrusor Smooth Muscle Function","volume":"364","author":"Provence","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.bmcl.2018.09.036","article-title":"Novel K(V)7 ion channel openers for the treatment of epilepsy and implications for detrusor tissue contraction","volume":"28","author":"Seefeld","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3389\/fphys.2020.01004","article-title":"Detrusor Smooth Muscle K(V)7 Channels: Emerging New Regulators of Urinary Bladder Function","volume":"11","author":"Malysz","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1368-5031.2005.00585.x","article-title":"Darifenacin in the treatment of overactive bladder","volume":"59","author":"Parsons","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"148403","DOI":"10.1155\/2012\/148403","article-title":"Evidence for Inhibitory Effects of Flupirtine, a Centrally Acting Analgesic, on Delayed Rectifier K+ Currents in Motor Neuron-Like Cells","volume":"2012","author":"Wu","year":"2012","journal-title":"Evid. Based Complement. Altern. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:31:39Z","timestamp":1760167899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":91,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222212399"],"URL":"https:\/\/doi.org\/10.3390\/ijms222212399","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}